6 Minute Read
This month, we offer commentary on two topics around Direct-to-Patient and the Impact of Maximum Fair Prices on the First 10 Medicare-Negotiated Drugs.
4 Minute Read
Independent pharmacies are struggling due to the Inflation Reduction Act (IRA), which increases drug costs and tightens payer restrictions, affecting their finances. The 340B program, meant to aid low-income...
6 Minute Read
Read the latest on Industry Updates, Biosimilar Barriers, and the Impact of Drug Price Negotiations.
4 Minute Read
Read the latest on IRA implications on rare disease, economic challenges underpinning drug shortages, and navigating the 340B saga.
4 Minute Read
Read the latest on how states influence drug pricing and access, specialty pharmacies evolution to supoprt cell & gene therapies, and Walgreens entering the CGT arena.
5 Minute Read
Discover the latest on IRA Part D Redesign Financial Implications, New Gene Therapies Give Newfound Hope for Patients, and Impact of Credit Card Fees in Government Pricing.
9 Minute Read
We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
5 Minute Read
We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
5 Minute Read
We explore the 10 most common challenges facing Market Access operations, based on over 15 years of experience with more than 250 pharma manufacturers.